30 Dec 2024 Precigen ActoBio Announces Additional Positive Interim Data from Phase 1b/2a Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes Member news
23 Dec 2024 Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis Member news
12 Dec 2024 Allegro’s osteoarthritis injectable shock absorbing gel demonstrates preclinical safety Member news
09 Dec 2024 Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Member news
09 Dec 2024 Therapeutic potential of a novel mixture of mRNA in nanoparticles overcomes tumor progression Member news
06 Dec 2024 Muna Therapeutics Announces Strategic Alliance with GSK to Accelerate Development of Novel Treatments for Alzheimer’s Disease Member news
More info? Ellen Telleir Communication Coordinator linkedin.com/in/ellentelleir/ +32 9 241 80 41 ellen.telleir@flanders.bio Contact us